{"pmid":32245869,"title":"Possible treatment of Covid-19 with a therapeutic vaccine.","text":["Possible treatment of Covid-19 with a therapeutic vaccine.","Vet Rec","Myint, Aung","Jones, Trevor","32245869"],"journal":"Vet Rec","authors":["Myint, Aung","Jones, Trevor"],"date":"2020-04-05T11:00:00Z","year":2020,"_id":"32245869","week":"202014|Mar 30 - Apr 05","doi":"10.1136/vr.m1302","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1663169699625566208,"score":7.6048946,"similar":[{"pmid":32221001,"title":"Possible method for the production of a Covid-19 vaccine.","text":["Possible method for the production of a Covid-19 vaccine.","Vet Rec","Myint, Aung","Jones, Trevor","32221001"],"journal":"Vet Rec","authors":["Myint, Aung","Jones, Trevor"],"date":"2020-03-30T11:00:00Z","year":2020,"_id":"32221001","week":"202014|Mar 30 - Apr 05","doi":"10.1136/vr.m1193","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1662624089081118722,"score":52.478752},{"pmid":32145386,"title":"Remdesivir as a possible therapeutic option for the COVID-19.","text":["Remdesivir as a possible therapeutic option for the COVID-19.","Travel Med Infect Dis","Al-Tawfiq, Jaffar A","Al-Homoud, Ali H","Memish, Ziad A","32145386"],"journal":"Travel Med Infect Dis","authors":["Al-Tawfiq, Jaffar A","Al-Homoud, Ali H","Memish, Ziad A"],"date":"2020-03-08T11:00:00Z","year":2020,"_id":"32145386","week":"202010|Mar 02 - Mar 08","doi":"10.1016/j.tmaid.2020.101615","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1662334543919579137,"score":48.831535},{"pmid":32227357,"title":"COVID-19 treatment by repurposing drugs until the vaccine is in sight.","text":["COVID-19 treatment by repurposing drugs until the vaccine is in sight.","Corona virus disease (COVID-19) has created pandemic in the world as declared by WHO on March 12, 2020. It is a viral disease caused by SARS-CoV 2 virus and has affected large populations in over 120 countries. There is no specific treatment available and management is empirical. Until such time that an effective vaccine is available for COVID-19 viral infection, one can repurpose known therapeutic drug molecules such as angiotensin receptor 2 blocker, a commonly used antihypertensive drug, to control COVID-19 virus from gaining entry into the host cell by blocking the angiotensin receptor. Clinical trials should also be undertaken to use statins, which are lipid-lowering drugs but have anti-inflammatory and immunomodulatory properties to prevent acute lung injury in COVID-19 infection.","Drug Dev Res","Phadke, Mrudula","Saunik, Sujata","32227357"],"abstract":["Corona virus disease (COVID-19) has created pandemic in the world as declared by WHO on March 12, 2020. It is a viral disease caused by SARS-CoV 2 virus and has affected large populations in over 120 countries. There is no specific treatment available and management is empirical. Until such time that an effective vaccine is available for COVID-19 viral infection, one can repurpose known therapeutic drug molecules such as angiotensin receptor 2 blocker, a commonly used antihypertensive drug, to control COVID-19 virus from gaining entry into the host cell by blocking the angiotensin receptor. Clinical trials should also be undertaken to use statins, which are lipid-lowering drugs but have anti-inflammatory and immunomodulatory properties to prevent acute lung injury in COVID-19 infection."],"journal":"Drug Dev Res","authors":["Phadke, Mrudula","Saunik, Sujata"],"date":"2020-04-01T11:00:00Z","year":2020,"_id":"32227357","week":"202014|Mar 30 - Apr 05","doi":"10.1002/ddr.21666","source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"_version_":1662819280276684802,"score":46.483486},{"pmid":32187489,"title":"Audio Interview: New Research on Possible Treatments for Covid-19.","text":["Audio Interview: New Research on Possible Treatments for Covid-19.","N Engl J Med","Rubin, Eric J","Baden, Lindsey R","Morrissey, Stephen","32187489"],"journal":"N Engl J Med","authors":["Rubin, Eric J","Baden, Lindsey R","Morrissey, Stephen"],"date":"2020-03-19T11:00:00Z","year":2020,"_id":"32187489","week":"202012|Mar 16 - Mar 22","doi":"10.1056/NEJMe2005759","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1662334543490711552,"score":44.833736},{"pmid":32104907,"title":"A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option.","text":["A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option.","In the past few decades, coronaviruses have risen as a global threat to public health. Currently, the outbreak of coronavirus disease-19 (COVID-19) from Wuhan caused a worldwide panic. There are no specific antiviral therapies for COVID-19. However, there are agents that were used during the severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) epidemics. We could learn from SARS and MERS. Lopinavir (LPV) is an effective agent that inhibits the protease activity of coronavirus. In this review, we discuss the literature on the efficacy of LPV in vitro and in vivo, especially in patients with SARS and MERS, so that we might clarify the potential for the use of LPV in patients with COVID-19.","J Med Virol","Yao, Tian-Tian","Qian, Jian-Dan","Zhu, Wen-Yan","Wang, Yan","Wang, Gui-Qiang","32104907"],"abstract":["In the past few decades, coronaviruses have risen as a global threat to public health. Currently, the outbreak of coronavirus disease-19 (COVID-19) from Wuhan caused a worldwide panic. There are no specific antiviral therapies for COVID-19. However, there are agents that were used during the severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) epidemics. We could learn from SARS and MERS. Lopinavir (LPV) is an effective agent that inhibits the protease activity of coronavirus. In this review, we discuss the literature on the efficacy of LPV in vitro and in vivo, especially in patients with SARS and MERS, so that we might clarify the potential for the use of LPV in patients with COVID-19."],"journal":"J Med Virol","authors":["Yao, Tian-Tian","Qian, Jian-Dan","Zhu, Wen-Yan","Wang, Yan","Wang, Gui-Qiang"],"date":"2020-02-28T11:00:00Z","year":2020,"_id":"32104907","week":"20209|Feb 24 - Mar 01","doi":"10.1002/jmv.25729","keywords":["COVID-19","MERS","SARS","coronavirus","lopinavir"],"source":"PubMed","locations":["Wuhan","vivo"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1662334544250929152,"score":40.58231}]}